Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TTR | P02766 | 3/20 | 0.40 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20621268 | 0.84 | HSD17B10 (0.41) | HSD17B10TSHRHPGDMAPK1ALOX15 | |
| SCHEMBL11038432 | 0.82 | HSD17B10 (0.52) | HSD17B10TSHRHPGDMAPK1ALOX15 | |
| SCHEMBL22989874 | 0.82 | CYP3A4 (0.35) | HSD17B10TSHRHPGDMAPK1CYP3A4 | |
| SCHEMBL25828290 | 0.77 | HSD17B10 (0.48) | HSD17B10TSHRHPGDMAPK1ALOX15 | |
| SCHEMBL24161818 | 0.77 | CYP3A4 (0.32) | MAPK1CYP3A4 | |
| SCHEMBL14753956 | 0.76 | POLB (0.38) | HSD17B10HPGDMAPK1SMN1; SMN2CYP2C19 | |
| SCHEMBL23491119 | 0.76 | AR (0.35) | HPGDSMN1; SMN2ALDH1A1TTRESR1 | |
| SCHEMBL13997274 | 0.75 | HSD17B10 (0.59) | HSD17B10TSHRHPGDMAPK1ALOX15 | |
| SCHEMBL11713810 | 0.75 | HSD17B10 (0.59) | HSD17B10TSHRHPGDMAPK1ALOX15 | |
| SCHEMBL21186738 | 0.71 | ALDH1A1 (0.40) | TSHRCYP3A4ALDH1A1MAPTADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3842433-B1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2023-11-01 | — | — | EP | disclosed |
| EP-3741756-B1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11655248-B2 | Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655248-B2 | Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| US-11453667-B2 | Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2022-09-27 | — | — | US | disclosed |
| US-20220298174-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-09-22 | — | — | US | disclosed |
| EP-4011886-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-06-15 | — | — | EP | disclosed |
| US-20210371411-A1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3842433-A1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | Medshine Discovery Inc. (CN) | 2021-06-30 | — | — | EP | disclosed |
| US-20210147418-A1 | Pyridone-Pyrimidine Derivative Acting As KRASG12C Mutein Inhibitor | MEDSHINE DISCOVERY INC (CN) | 2021-05-20 | — | — | US | disclosed |
| WO-2021052499-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
| WO-2021027943-A1 | PYRIMIDINOPYRIDAZINONE DERIVATIVE AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-02-18 | — | — | WO | disclosed |
| WO-2021023154-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-02-11 | — | — | WO | disclosed |
| EP-3741756-A1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | Medshine Discovery Inc. (CN) | 2020-11-25 | — | — | EP | disclosed |
| WO-2019141250-A1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | 南京明德新药研发股份有限公司 | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | HSD17B10 2306/4885TSHR 4093/4885HPGD 1429/4885 |
| US-11453667-B2 | Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor | KRAS, NRAS, MSH2 | HSD17B10 3330/4885TSHR 4483/4885HPGD 678/4885 |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | HSD17B10 2306/4885TSHR 4093/4885HPGD 1429/4885 |
| US-20220298174-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | HSD17B10 3734/4885TSHR 3970/4885HPGD 2741/4885 |
| US-11655248-B2 | Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor | KRAS, NRAS, MSH2 | HSD17B10 3795/4885TSHR 4157/4885HPGD 1086/4885 |
| US-20210147418-A1 | Pyridone-Pyrimidine Derivative Acting As KRASG12C Mutein Inhibitor | KRAS, NRAS, MSH2 | HSD17B10 3330/4885TSHR 4483/4885HPGD 678/4885 |
| US-20210371411-A1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | KRAS, NRAS, MSH2 | HSD17B10 3330/4885TSHR 4483/4885HPGD 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.